VTA was attempted with programmed ventricular stimulation, as previously described. 12 Briefly, 1-3 extra-stimuli at twice the end-diastolic threshold were delivered following ventricular pacing at 2 different cycle lengths, first at the right ventricular apex, then at the right ventricular outflow tract. If VTA was not induced, the same protocol without 3 extra-stimuli was repeated during intravenous administration of isoproterenol at a dose of 20 g/h. If VTA was not induced from the right ventricle, programmed stimulation was attempted in the left ventricle. The endpoint of the stimulation was induction of a sustained VTA (≥30 s) or completion of the protocol.
Nifekalant Administration
After VTA was induced during the first EPS, the effects of nifekalant hydrochloride were studied. Nifekalant was administered at an initial dose of 0.3 mg· kg -1 ·(5 min) -1 , followed by infusion at 0.4 mg·kg -1 ·h -1 with careful ECG monitoring because of the risk of torsade de pointes. 13 Programmed electrical stimulation was repeated with the same protocol and endpoint as described before. Patients in whom VTA became non-inducible were defined as responders to nifekalant.
Sotalol Treatment
After the first EPS, sotalol was administered, regardless of the efficacy of nifekalant for inducible VTA. The drug was begun at an initial dose of 80 mg/day, and then increased up to 240 mg/day in increments of 40-80 mg/5 days, as tolerated. A 12-lead ECG was recorded before each increase in dose during the upward drug titration. The maximum tolerated dose was defined by intolerant hypotension, marked bradycardia, or prolongation of the QT interval and/or corrected QT (QTc) interval >550 ms. The EPS was repeated at least 5-days after administration of the final dose. The stimulation protocol and endpoints of the followup EPS were identical to those of the first study.
Patients in whom VTA was not inducible during the second EPS were considered to be drug responders and were changed to long-term sotalol treatment. If sustained VTA was induced during the second EPS, the patient was considered a non-responder. In non-responders who needed further treatment for uncontrolled VTA, sotalol was exchanged for another drug. Non-responders without any complications or VTA recurrence also continued with sotalol. Patients who discontinued sotalol therapy were excluded from the analysis of long-term sotalol therapy.
Follow-up
Patients were followed monthly in the outpatient clinic. ICD data was checked every 3 months and at the time of any ICD discharge.
Data Analysis
We compared the efficacy of nifekalant and sotalol for inducible VTA. We also studied whether the effects of nifekalant in inducible VTA could predict the clinical effects of sotalol. All values are presented as means ± SD. Paired or unpaired values were compared by appropriate Student's t-test or 1-way analysis of variance. Time-to-event curves describing the proportion of patients who remained event-free were constructed using the Kaplan-Meier method and compared using the log-rank test. A p-value <0.05 was considered statistically significant.
Results

Electrophysiologic Effects
The electrophysiological effects of nifekalant and sotalol are shown in Table 1 . The heart rate was slowed by sotalol but not by nifekalant. The QT interval, QTc interval, and effective refractory period (ERP) at the right ventricular apex were prolonged similarly by nifekalant and sotalol (p= NS for nifekalant vs sotalol).
Efficacy of Nifekalant for Inducible VTA
In the first EPS, VTA was inducible before nifekalant administration in all of the 14 patients, and isoproterenol administration was not required for VTA induction in any of them. After nifekalant administration, VTA was not induced in 5 patients ( Table 2 , patients 1-5), whereas VTA remained inducible without isoproterenol in the remaining 9 patients (patients [6] [7] [8] [9] [10] [11] [12] [13] [14] . The clinical characteristics of the responders and non-responders to nifekalant did not differ (Table 3 ). Of the 5 responding patients, 1 had inducible monomorphic VT before administration of nifekalant, 3 had polymorphic VT, and 1 exhibited both types of VT (Table 2) . Of the 8 non-responding patients in whom monomorphic VT was induced during nifekalant administration, 7 patients had inducible monomorphic VT before nifekalant, and 1 exhibited both monomorphic and polymorphic VT. In 7 of the 8 patients in whom monomorphic VT was induced during nifekalant administration, the morphology was identical to those induced before the administration, but was different in the remaining patient. Polymorphic VT was induced during nifekalant administration in 1 patient who had polymorphic VT before nifekalant. Nifekalant slowed the rate of monomorphic VT from 209±21 to 196±19 beats/min, but this effect was not significant (p=0.09). The number of extra-stimuli for induction of VT was increased by nifekalant in 4 of the 9 non-responders.
The QT or QTc interval either before or during nifekalant administration did not differ between the patients who responded to nifekalant and those who did not (Table 3) . The ERP both before and during nifekalant administration were significantly longer in the non-responders than the responders (Table 3) . However, there was no difference in the prolongation of the ERP between the responders and the non-responders (12±9% vs 7±7%, p= NS).
Efficacy of Sotalol for Inducible VTA
During sotalol therapy at an average maintenance dose of 133±53 mg/day, the second EPS was conducted 35±10 days after the first study. Before the second study, VTA did not recur in any patients. In 4 of the 5 patients responding to nifekalant, sotalol also suppressed the induction of VTA (patients 1-4) . In all of the 9 patients who did not respond to nifekalant, VTA was induced during sotalol administration. In 7 of the 9 cases of inducible monomorphic VT during sotalol therapy, the QRS morphology was identical to that induced before nifekalant administration during the first EPS, but was different in the remaining 2 patients. Sotalol did not change the VT rate (from 205±18 to 200± 27 beats/min, p=0.55). Of 9 patients in whom VTA was refractory to both nifekalant and sotalol, the inducibility of VTA became more difficult in 3 patients during sotalol administration compared with nifekalant (ie, the number of extra-stimuli needed to induce VTA increased in 1 patient and isoproterenol was needed in 2 patients, whereas VTA became easier to induce in 2 patients). Nifekalant predicted the response of inducible VTA to sotalol during EPS in 13 of 14 patients (93%) (specificity 80%, sensitivity 100%).
Long-Term Sotalol Treatment
Sotalol treatment was continued at a similar dose to that used in the EPS (mean dose 122±45 mg/day), combined with the ICD in 11 patients: 4 responders and 7 nonresponders to sotalol. Three non-responders discontinued sotalol because of a change to another drug (patients 6 and 7) or patient disagreement with long-term treatment (patient 5). During a mean follow-up of 46±11 months, monomorphic VT recurred in 3 (patients 8-10) among 7 non-responders (43%), but did not recur in responders (Fig 1) . No deaths occurred from any causes, nor did any of the patients need to discontinue long-term sotalol treatment because of adverse effects, including torsade de pointes.
Discussion
This is the first report, to our knowledge, of a comparison of the effects of nifekalant to sotalol in humans. Our results suggest that the response to nifekalant may predict the short-and long-term efficacy of sotalol for suppressing VTA.
Electrophysiologic Effects
Both nifekalant and sotalol block the rapid component of the delayed rectifier potassium current. 14, 15 In the present study, nifekalant and sotalol similarly prolonged the QT and QTc intervals, and the ventricular refractory period. Therefore, the 2 drugs prolonged the duration of the action potential, mainly by blocking the potassium current, to a similar extent. Sotalol also has -blocking properties, whereas nifekalant is a pure potassium channel blocker. In some of the patients in whom VTA was induced without isoproterenol during nifekalant administration, isoproterenol was required to induce VTA during sotalol therapy, although sotalol could not completely suppress inducible VTA in any of the patients who did not respond to nifekalant. The -blocking properties of sotalol may have some of the beneficial effects on VTA that have been shown with other -blockers. 16, 17 The ERP was shorter in patients who responded to nifekalant than in the non-responders, but the drug prolonged the QT interval and the ERP similarly in both groups. However, the precise role of a prolonged refractory period or action potential duration in rendering the VTA non-inducible was not clear.
VTA Management
Antiarrhythmic drugs remain necessary in certain ICD recipients, and class III drugs can play a role in this capacity. [1] [2] [3] 18 Although nifekalant is effective in suppressing VTA, it cannot be used for chronic medication in conjunction with ICD because it can only be administered intravenously. Sotalol is a potential candidate for replacement [19] [20] [21] because recent reports have shown that it can suppress ICD shocks for VTA and reduce mortality. 10, 11 Although an EPS was performed to predict drug efficacy for VTA in this study, the appropriateness of serial drugtesting has been called into question. 9, 22 The response to programmed stimulation during drug administration may select patients at lower risk of VTA recurrence. However, EPS-guided antiarrhythmic therapy was found to be more effective than the absence of antiarrhythmic therapy in some primary prevention trials and our secondary prevention trial. 11, 23 In the present study, the efficacy of sotalol for suppressing VTA recurrence was not different between responders and non-responders despite the lack of recurrence in the responders. The small number of patients may have affected the results.
Amiodarone is another candidate to replace nifekalant, but there have been few reports describing its efficacy for reducting ICD shocks. The acute and chronic effects of amiodarone differ, and it is difficult to predict its efficacy. 24, 25 Therefore, the drug is usually administered empirically. 26 Moreover, both sotalol and nifekalant have been reported to decrease the defibrillation threshold, whereas amiodarone may increase it. [27] [28] [29] The results of this study suggest that in patients in whom VTA is suppressed by nifekalant, sotalol is very likely to be efficacious. Thus, the response of inducible VTA to nifekalant may provide useful information about the clinical efficacy of sotalol treatment.
Study Limitations
The number of patients studied was small and a control group was absent. Assessment of statistical analysis may be difficult because of the small population and the variability of heart disease. The role of EPS in drug selection remains controversial. 
